Lineage Cell Therapeutics, Inc.
AMEXLineage Cell Therapeutics heads into its May 14 earnings print riding a wall of analyst buy ratings, while the stock itself has quietly slipped 10% over the past month. The analyst community is uniformly bullish — all six covering analysts carry Buy ratings, with a mean price target of $5.14 against a current price of $1.33. Canaccord Genuity initiated coverage on April 28 with a…
Snapshot as of 25 Jun 2026
Lineage Cell Therapeutics heads into its May 14 earnings print riding a wall of analyst buy ratings, while the stock itself has quietly slipped 10% over the past month. The analyst community is uniformly bullish — all…
LCTX heads into its May 14 earnings report with fresh analyst coverage and a short base that remains stubbornly elevated — a combination that makes the next two weeks worth watching closely. The most notable…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for LCTX — free to start on ORTEX.
Sign up for free →Open LCTX on ORTEX